Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib with or without Niraparib in Platinum-Resistant Ovarian Cancer
NCT05198804Phase 2Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of azenosertib in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Zentalis Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 6 months, Safety and Tolerability of ZN-c3 monotherapy at 12 months and 1 more. Started Jan 2022; status: completed.
02
Drugs
azenosertib
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05198804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198804.